Global Mitogen Activated Protein Kinase 8 Market Overview:
MAPK8 (Mitogen-Activated Protein Kinase 8) is a Protein Coding gene. Diseases like Fatty Liver Disease and Hepatitis C are associated with MAPK8. Serine/threonine-protein kinase is involved in various processes such as cell proliferation, differentiation, migration, transformation, and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. The MAP kinases act as an integration point for multiple biochemical signals involved with a variety of cellular processes, the activation of this kinase by tumor necrosis factor-alpha if required for TNF-alpha induced apoptosis. Some of the key players profiled in the study are Bristol Myers Squibb Company (Celgene Corp) (United States), Eisai Co., Ltd. (Japan), OPKO Health (United States), Xigen SA (Switzerland) and Fulcrum Therapeutics (United States).
On the basis of geography, the market of Mitogen Activated Protein Kinase 8 has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
- Rising Demand due to Growing Prevalences of the Cancer and Gene Study
- Increasing Investment in Healthcare Sector
- Increasing Number Cases Related to The Breast Cancer
- High Adoption of CC-90001
- Regulatory Concerns with Mitogen-Activated Protein Kinase 8
- High Demand From the Developing Countries
- Growing Demand due to Ongoing Research and Development activities across the World
- Technical Problems in Maintenance and Handling of Mitogen-Activated Protein Kinase 8
Major Market Developments:
On 29 January 2020, Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to losmapimod, a selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum also announced the issuance of U.S. patent 10,537,560 with claims covering the use of other p38 kinase inhibitors for the treatment of FSHD.
Research and Development Institutes, Potential Investors, Regulatory Bodies, Hospitals, National Laboratories and Others
Major Objectives Focused through this Study
To define, describe, and forecast the Global Mitogen Activated Protein Kinase 8 market on the basis of product [CC-90001, SR-3306, ER-358063, WBZ-4 and Others] , application [Breast Cancer, Alzheimer's Disease, Acute Renal Failure, Liver Failure and Others], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Mitogen Activated Protein Kinase 8 market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Mitogen Activated Protein Kinase 8 industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Mitogen Activated Protein Kinase 8 market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.